# OPTIMAL: OPTimising renal outcome in Myeloma renal failure

Submission date 19/06/2014	<b>Recruitment status</b> No longer recruiting	<ul><li>[X] Prospectively registered</li><li>[X] Protocol</li></ul>		
Registration date 19/06/2014	<b>Overall study status</b> Completed	<ul> <li>[] Statistical analysis plan</li> <li>[X] Results</li> </ul>		
Last Edited 12/12/2022	<b>Condition category</b> Cancer	Individual participant data		

#### Plain English summary of protocol

http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-bortezomib-and-thalidomide-in-people-with-myeloma-whose-kidneys-are-not-working-well-optimal

## **Contact information**

**Type(s)** Scientific

**Contact name** Dr Karthik Ramasamy

#### **Contact details**

Late Phase Haematology Research Team Cancer & Haematology Centre Churchill Hospital Old Road Headington Oxford United Kingdom OX3 7LE

OPTIMAL.trial@nhs.net

## Additional identifiers

**EudraCT/CTIS number** 2012-003947-31

#### **IRAS number**

ClinicalTrials.gov number NCT02424851

### Study information

#### Scientific Title

A study of Thalidomide, Bendamustine, and Dexamethasone (BTD) vs Bortezomib, Bendamustine, and Dexamethasone (BBD) in patients with renal failure defined as a GFR below 30 ml/min

#### Acronym

OPTIMAL

#### **Study objectives**

Renal impairment is a life-threatening complication of myeloma. Up to 20-25% of patients will present at myeloma diagnosis with renal dysfunction.

In this Phase II study, 120 newly diagnosed myeloma patients with eGFR less than 30 ml/min from approximately 20 centres will be randomised to receive either Thalidomide or Bortezomib; all patients will receive bendamustine and dexamethasone in three weekly cycles. All patients will receive a minimum of four cycles.

Aims:

1. Establish whether proteasomal inhibition (bortezomib) or IMiD (thalidomide) based therapy achieves threshold reduction of sFLC in a significant majority of patients

2. Establish whether sFLC response to the first two cycles (early responder) predicts

haematological and renal response to the next two cycles of therapy

3. Establish an early time point for assessment of sFLC reduction as a biomarker for response

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Northeast Newcastle and North Tyneside2 (NNT2) Committee, 03/03/2014, ref:13-NE-0361;

#### Study design

Randomised; Interventional; Design type: Process of Care

**Primary study design** Interventional

**Secondary study design** Randomised controlled trial

**Study setting(s)** Hospital

**Study type(s)** Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

#### Health condition(s) or problem(s) studied

Topic: Cancer; Subtopic: Haematological Oncology; Disease: Myeloma

#### Interventions

BTD vs BBD, Thalidomide + Bendamustine + Dexamethasone (BTD) vs Bortezomib + Bendamustine + Dexamethasone (BBD); Follow Up Length: 12 month(s); Study Entry: Single Randomisation only

#### Added 16/02/2017:

Potential eligible participants are screened and baseline assessments undertaken including: medical history; treatment history; concomitant medications; bone imaging; local laboratory evaluations.

Eligible patients are randomised to one of two treatment groups, stratified by age and Chronic Kidney Disease (CKD) stage.

Group 1: Bortezomib, Bendamustine and Dexamethasone (BBD) Participants receive Bortezomib 1.3 mg/m2 subcutaneous on days 1, 4, 8 and 11. They receive Bendamustine 60 mg/m2 intravenous infusion on days 1 and 8. They also take Dexamethasone 40 mg daily orally on days 1-2,4-5,8-9,11-12.

Group 2: Thalidomide, Bendamustine and Dexamethasone (BTD) Participants take Thalidomide 100 mg daily p.o. preferably at night for 21 days. They receive Bendamustine 60 mg/m2 intravenous infusion on days 1 and 8. They also take Dexamethasone 40 mg daily orally on days 1-2,4-5,8-9,11-12.

Participants are randomised to receive up to 4 cycles of either Bortezomib (Arm A) or Thalidomide (Arm B) (21 days in each cycle). All participants receive Bendamustine and Dexamethasone as combination therapy. Participants not considered suitable for autologous stem cell transplant (ASCT) may be given a further two cycles of their allocated treatment (up to 6 cycles in total).

During treatment assessments are undertaken including: physical examination; concomitant medications, local laboratory evaluations and adverse event reporting.

All participants who have received at least 2 cycles of their allocated treatment are followed up at 1 month post end of treatment (approximately 30 days after last dose) and 12 months post randomisation. These assessments include physical examination, disease status, treatment efficacy, overall survival and local laboratory evaluations.

Participants are asked to complete a validated (EQ-5D- 3L) Quality of Life questionnaire at screening (baseline), on day 1 of each treatment cycle and at 1 month and 12 month follow-up.

Central laboratory samples are collected at screening (baseline), during treatment and at 1 month follow up and sent to both Oxford and Birmingham.

#### Intervention Type

Drug

#### Phase

#### Not Applicable

#### Drug/device/biological/vaccine name(s)

Thalidomide + Bendamustine + Dexamethasone (BTD), Bortezomib + Bendamustine + Dexamethasone (BBD)

#### Primary outcome measure

Response defined as >50% reduction (from baseline) in sFLC week 6 (end of cycle 2)

#### Added 16/02/2017:

 Serum free light chain response is measured as the proportion of participants with response defined as >50% reduction (from baseline) in sFLC week 6 (end of cycle 2).
 Myeloma response is measured by the renal response (Modified IMWG Uniform Criteria Of Response and Progression) at the end of 4 cycles of therapy

#### Secondary outcome measures

Renal response at end of four cycles of therapy.

#### Added 16/02/2017:

1. Overall response and correlation with monoclonal protein the urine is measured by the sFLC response at week 1, 2, 3, 4, 5, 6, 9 and 12

2. Haematological and non-hameatological toxicity in both arms is preasured by haematological responses adverse Events (NCI CTCAE v4.0) criteria

Survival at 1 month post end of treatment and 12 months post randomisation
 change in renal function between the two treatment regimens is assessed by the renal response (defined by the IMWG renal response criteria) at the end of cycle 2 and cycle 4
 Treatment effects on other patient reported outcomes is measured by the EQ-5D-3L Quality of life questionnaire at baseline, start of each treatment cycle and at 1 and 12 months post follow-up

#### Overall study start date

06/06/2014

#### Completion date

01/06/2020

## Eligibility

#### Key inclusion criteria

- 1. Patients attending NHS haemato-oncology centres
- 2. Patients with newly diagnosed symptomatic myeloma and renal failure
- 3. Patients willing and able to give written informed consent
- 4. Chronic kidney disease stage 4 or 5
- 5. GFR <30 ml/min

6. A number of patients with newly diagnosed myeloma and renal failure will have a pre-existing medical condition (hypertension, diabetes etc) causing renal damage. Where there is a medical condition (eg. hypertension, diabetes) which may cause renal damage, there must have been a further decline (=15 ml/min) between previous steady state and the study screening

7. Women of childbearing potential (WCBP) and male participants whose partner is a WCBP must be prepared to use contraception in accordance with (and consent) to the Celgene-approved process for thalidomide and lenalidomide Risk Management and Pregnancy Prevention Programme

8. WCBP must have a negative pregnancy test performed by a healthcare professional in accordance with the Celgene-approved process for thalidomide and lenalidomide Risk Management and Pregnancy Prevention

9. Free of prior malignancies for = 2 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, localised prostate cancer or carcinoma 'in situ' of the cervix or breast

10. In the Investigator's opinion, is able and willing to comply with all trial requirements 11. Willing to allow his or her GP and consultant, if appropriate, to be notified of participation in the trial

#### Participant type(s)

Patient

#### Age group

Adult

Sex

Both

#### Target number of participants

Planned Sample Size: 120; UK Sample Size: 120

#### Total final enrolment

31

#### Key exclusion criteria

1. Female patient who is pregnant, lactating or planning pregnancy during the course of the trial or the female partner of a male participant planning a pregnancy during the course of the trial

- 2. Age <18 years
- 3. Known allergy to investigational drugs

4. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial

5. Any of the following laboratory abnormalities:

5.1. Absolute neutrophil count (ANC) <1.0 x 10(9)/L

- 5.2. Platelet count <75 x 10(9)/L
- 5.3. Serum SGOT/AST or SGPT/ALT >3 x upper limit of normal

6. Use of any standard/experimental anti-myeloma drug therapy 14 days prior to trial entry 7. CKD <4

8. Intention to use a physical method of serum free light chain removal such as plasma exchange or high cut-off dialysis

9. Grade 2 neuropathy (NCICTCAE v 4.0) or more will preclude use of thalidomide and bortezomib 10. Participants who have participated in another research trial involving an investigational product in the past 12 weeks.

#### Date of first enrolment

21/03/2015

### Date of final enrolment

31/03/2019

### Locations

#### **Countries of recruitment** England

United Kingdom

### Study participating centre

**Churchill Hospital, Oxford (lead site)** Oxford University Hospitals NHS Foundation Trust Old Road Oxford United Kingdom OX3 7LE

#### Study participating centre

St Helier Hospital

Epsom and St Helier University Hospitals NHS Trust Wrythe Lane Sutton Carshalton United Kingdom SM5 1AA

#### Study participating centre Queen Alexandria Hospital

Portsmouth Hospitals NHS Trust Southwick Hill Road Portsmouth United Kingdom PO6 3LY

**Study participating centre Basingstoke and North Hampshire Hospital** Hampshire Hospitals NHS Foundation Trust Aldermaston Road Basingstoke United Kingdom RG24 9NA

#### Study participating centre Kent and Canterbury Hospital

East Kent Hospitals University NHS Foundation Trust Ethelbert Road Canterbury Kent Canterbury United Kingdom CT1 3NG

**Study participating centre Royal Liverpool Hospital** Royal Liverpool Hospital and Broadgreen University Hospitals NHS Trust Prescot Street Liverpool United Kingdom L7 8XP

### Sponsor information

**Organisation** Oxford University Hospitals NHS Foundation Trust

#### Sponsor details

Headley Way Headington Oxford England United Kingdom OX3 9DU

**Sponsor type** Hospital/treatment centre

Website http://www.ouh.nhs.uk/

ROR https://ror.org/03h2bh287

### Funder(s)

Funder type

Charity

Funder Name Bloodwise

Alternative Name(s)

**Funding Body Type** Private sector organisation

**Funding Body Subtype** Other non-profit organizations

**Location** United Kingdom

Funder Name Janssen Cilag International NV

### **Results and Publications**

#### Publication and dissemination plan

Final study report and publication planned in a high-impact peer reviewed journal.

# Intention to publish date 01/12/2020

#### 01/12/2020

#### Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study during this study will be included in the subsequent results publication.

#### IPD sharing plan summary

Other

#### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<u>Basic results</u>	EU Clinical Trials Register results	23/05/2021	20/05/2022	No	No
Basic results	ClinicalTrials.gov results	27/01/2022	23/05/2022	Νο	No
<u>Protocol file</u>	version 12.0	01/08/2017	07/07/2022	No	No
Protocol article	results	29/11/2022	12/12/2022	Yes	No